Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
DICUMAROL vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin clot formation and extension.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
Loading dose: 5000 units IV bolus, then continuous IV infusion at 12,000-18,000 units/24h (10-15 units/kg/h). Adjust to target aPTT 60-80 seconds.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
The terminal elimination half-life of heparin is dose- and concentration-dependent, averaging 1-2 hours after intravenous administration. At therapeutic doses, the half-life is approximately 1.5 hours; with higher doses, it can extend to 2.5-3 hours. The half-life is prolonged in patients with hepatic or renal impairment.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Heparin is eliminated primarily via the reticuloendothelial system and liver, with renal excretion of metabolites accounting for approximately 50-60% of the dose. A small fraction (up to 5%) is excreted unchanged in urine. No significant biliary or fecal elimination.
Category C
Category A/B
Anticoagulant
Anticoagulant